RTK

Many of the Axon Ligands™ in this class of compounds target receptors of various growth factors, such as EGF, VEGF, and PDGF. These receptors are members of the class of enzyme linked receptors, which, as integral membrane proteins, possess both receptor functionality (extra-cellular) as well as enzymatic catalytic functionality (intracellular)[1],[2]. The majority of the enzymatic activity of this class of receptors is characterized by kinase-like activity. Based on this feature, five main classes can be distinguished[3]: Receptor Tyrosine Kinases (RTKs), and Receptor Serine/Threonine Kinases (RSTKs, participating in MAPK and TGF-beta signaling pathways, among others) are well known. Additionally, there are classes of Receptor Guanylyl Cyclases, Histidine Kinase associated Receptors (receptors that associate with proteins that have histidine kinase activity), and finally a class of Tyrosine Kinase associated Receptors (e.g. Cytokine Receptors). In addition, some transmembrane tyrosine phosphatases (Receptor-like) Protein Tyrosine Phosphatases (PTPs)), which remove phosphate from phosphotyrosine side chains of specific proteins, are thought to function as receptors, although for the most part their ligands are unknown. Within each of these main classes, sub-classes exist, based on the specific endogenous ligands. Many of the enzyme linked receptors play a role in the regulation of cell proliferation, programmed cell death (apoptosis), cell differentiation, and embryonic development, and therefore are of great interest as targets for the treatment of cancer[4]. Furthermore, malfunctioning of receptors of this kind is associated with the development of neurodegenerative diseases, such as multiple sclerosis and Alzheimer's disease[5].


[1] Catalytic Receptors. S.P.H. Alexander, A. Mathie, and J.A. Peters. Br. J. Pharmacol. 2007, 150(S1): S122–S127. 
[2] Cell Signaling by Receptor Tyrosine Kinases. M.A. Lemmon, J. Schlessinger. Cell 2010, 141, 1117-1134.
[3] Molecular Biology of the Cell. 4th edition. Alberts B, Johnson A, Lewis J, et al.New York:Garland Science; 2002.
[4] Tyrosine kinase receptors as attractive targets of cancer therapy. Bennasroune A, Gardin A., Aunis D., Crémel G., Hubert P. Crit. Rev. Oncol. Hematol. 2004, 50, 23-38.
[5] The EGF receptor family: spearheading a merger of signaling and therapeutics. Bublil E.M., Yarden Y. Curr. Opin. Cell Biol. 2007, 19,124-134.

11 Item(s)

per page
Axon ID Name Description From price
2849 Apatinib Inhibitor of VEGFR2 €125.00
1850 BMS 540215 Inhibitor of VEGFR (subtype 2 and 3 selective) €110.00
2837 BMS 605541 Potent, selective, orally active, and ATP-competitive VEGFR2 inhibitor €90.00
1864 Brivanib alaninate Prodrug of BMS 540215; Inhibitor of VEGF €105.00
1461 Cediranib VEGFR tyrosine kinase inhibitor €70.00
1662 CP 547632 VEGFR2 tyrosine kinase inhibitor €105.00
1963 LY 573636 Anti-tumor agent; causes growth arrest and apoptosis €95.00
2865 NVP-ACC789 Inhibitor of VEGFR2 €95.00
1717 Tivozanib VEGFR1, 2, and 3 tyrosine kinase inhibitor €99.00
1637 Vatalanib VEGFR tyrosine kinase inhibitor €75.00
1978 ZM 323881 hydrochloride Inhibitor of VEGFR2 €105.00

11 Item(s)

per page
Please wait...